Dec 10 (Reuters) - A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest. Patients in the trial had received initial treatments that eliminated nearly all of their cancer cells.

Summer is the ideal chance to investigate new objections and make extraordinary recollections. Whether you incline toward unwinding on a flawless

Picking the right gaming PC can be an overwhelming undertaking with the plenty of choices accessible on the lookout. These